Risk of fracture in patients with Charcot-Marie-Tooth disease

ABSTRACT Introduction: In this study we evaluated fracture risk in patients with Charcot–Marie–Tooth (CMT) disease. Methods: We conducted a retrospective cohort study using the UK Clinical Practice Research Datalink (1987–2012). Each patient with CMT disease was matched with up to 6 patients without...

Full description

Saved in:
Bibliographic Details
Published inMuscle & nerve Vol. 50; no. 6; pp. 919 - 924
Main Authors Pouwels, Sander, de Boer, Anthonius, Leufkens, Hubert G.M., Weber, Wim E.J., Cooper, Cyrus, de Vries, Frank
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.12.2014
Wiley Subscription Services, Inc
Subjects
Adult
Bone density
Bone Density - physiology
Case-Control Studies
Charcot-Marie-Tooth disease
Charcot-Marie-Tooth Disease - complications
Cohort Studies
cohort study
Confidence intervals
epidemiology
epidemiology, fracture
Female
Follow-Up Studies
fracture
Fractures
Fractures, Bone - epidemiology
Fractures, Bone - physiopathology
Humans
Male
Middle Aged
Older people
Osteoporosis
Outcome Assessment, Health Care
Retrospective Studies
Risk Factors
Studies
cohort study
epidemiology, fracture
osteoporosis
Charcot-Marie-Tooth disease
Online AccessGet full text

Cover

More Information
Summary:ABSTRACT Introduction: In this study we evaluated fracture risk in patients with Charcot–Marie–Tooth (CMT) disease. Methods: We conducted a retrospective cohort study using the UK Clinical Practice Research Datalink (1987–2012). Each patient with CMT disease was matched with up to 6 patients without a history of CMT disease. The outcome measure was fractures. Results: The risk of non‐osteoporotic fracture was statistically significantly increased [adjusted hazard ratio (AHR) 1.47, 95% confidence interval (CI) 1.01–2.14], whereas risk of any and osteoporotic fracture did not reach statistical significance compared with control patients [AHR 1.31 (95% CI 0.98–1.74) and AHR 1.10 (95% CI 0.69–1.74), respectively]. Conclusions: CMT patients have a 1.5‐fold increased risk for non‐osteoporotic fracture. Studies with larger numbers of CMT patients and with additional data on CMT subtype, bone mineral density, and functional status should be performed to confirm a true association between CMT and an increased risk of fracture. Muscle Nerve 50: 919–924, 2014
Bibliography:istex:D74294F419907F6BAD35AD0F4E5CD483AADFB9C1
ark:/67375/WNG-TFK0JVWK-7
ArticleID:MUS24240
The Division of Pharmacoepidemiology and Clinical Pharmacology employs S.P., A.d.B., and F.d.V., and has received unrestricted funding from The Netherlands Organisation for Health Research and Development (ZonMW), the Dutch Health Care Insurance Board (CVZ), the Royal Dutch Pharmacists Association (KNMP), the private–public‐funded Top Institute Pharma
which includes co‐funding from universities, government, and industry; the EU Innovative Medicines Initiative (IMI); the EU 7th Framework Program (FP7); and the Dutch Ministry of Health and Industry (including GlaxoSmithKline, Pfizer, and others). H.G.M.L. is a researcher at the WHO Collaborating Centre for Pharmaceutical Policy & Regulation, which receives no direct funding or donations from private parties, including the pharmaceutical industry. Research funding from public–private partnerships, including IMI, Top Institute Pharma, is accepted under the condition that no company‐specific product or company‐related study is conducted. The Centre has received unrestricted research funding from public sources, including the ZonMW, the CVZ, EU FP7, the Dutch Medicines Evaluation Board, and the Dutch Ministry of Health. C.C. and W.E.J.W. report no disclosures.
www.tipharma.nl
Disclosure
This work was funded in part by the European Calcified Tissue Society, and the NIHR, Biomedical Research Unit in Musculoskeletal Sciences, Nuffield Orthopaedic Centre, Oxford, UK.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0148-639X
1097-4598
DOI:10.1002/mus.24240